Publications

5539 Results

Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT)

Authors
MS Lucia;A Darke;P Goodman;C Tangen;CA Coltman;IM Thompson
Journal / Conference
Journal of Urology 173(4):451 (#1664)
Year
2005
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Prostate specific antigen (PSA) as a predictor of adverse pathological features at prostatectomy in the Prostate Cancer Prevention Trial (PCPT)

Authors
MS Lucia;P Goodman;C Tangen;CA Coltman;IM Thompson
Journal / Conference
Journal of Urology 173(4):143 (#525)
Year
2005
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Short-and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) trial

Authors
KA Hayden;CM Moinpour;J Faulkner;CM Tangen;ED Canby-Hagino;D Lemmon;S Breslin;IM Thompson;ED Crawford
Journal / Conference
Proc of the ASCO, JCO 23(16S):391s (#4556)
Year
2005
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8994 (EST-C-0690) (INT-0086)

Prognostic value of cell cycle regulators p27 and cyclin E: tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313

Authors
PL Porter;W Barlow;IT Yeh;MG Lin;X Yuan;JN Ingle;CL Shapiro;GP Sledge;RB Livingston;DF Hayes
Journal / Conference
Proc of the ASCO, JCO 23(16S):5s (#507)
Year
2005
Research Committee(s)
Breast
Study Number(s)
SWOG-9313

Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received "maintenance therapy"

Authors
PY Liu;DS Alberts;BJ Monk;M Brady;M Markman
Journal / Conference
Proc of the ASO, JCO 23(16S):458s (#5013)
Year
2005
Research Committee(s)
Gynecologic
Study Number(s)
S9701

Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504)

Authors
DR Gandara;K Chansky;LE Gaspar;KS Albain;PN Lara;J Crowley
Journal / Conference
Proc of the ASCO, JCO 23(16S):635s (#7059)
Year
2005
Research Committee(s)
Lung
Study Number(s)
SWOG-9504

Clinical benefit of Imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial.

Authors
ME Blackstein;C Rankin;C Fletcher;M Heinrich;R Benjamin;M von Mehren;C Blanke;JA Fletcher;E Borden;G Demetri
Journal / Conference
Proc of the ASCO, JCO 23(16S):818s (#9010)
Year
2005
Research Committee(s)
Sarcoma
Study Number(s)
S0033

Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the phase III intergroup study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST)

Authors
P Dileo;CJ Rankin;RS Benjamin;M von Mehren;C Blanke;V Bramwell;R Maki;C Fletcher;EC Borden;GD Demetri
Journal / Conference
Proc of the ASCO, JCO 23(16S):824s (#9032)
Year
2005
Research Committee(s)
Sarcoma
Study Number(s)
S0033

SWOG S0102: a phase II study of docetaxel (DOC) and vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer

Authors
J Gralow;S Green;D Lew;W Barlow;KA Dammann;G Somlo;S Rivkin;S Taylor;L Wong;R Livingston
Journal / Conference
Proc of the ASCO, JCO 23(16S):20s (#567)
Year
2005
Research Committee(s)
Breast
Study Number(s)
S0102

Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108

Authors
AT Stopeck;W Bellamy;JM Unger;L Rimsza;M Iannone;RI Fisher;TP Miller
Journal / Conference
Proc of the ASCO, JCO 23(16S):583s (#6592)
Year
2005
Research Committee(s)
Lymphoma
Study Number(s)
S0108